The head of German pharmaceutical company BioNTech said Monday that there is no need to waive patents on coronavirus vaccines because manufacturers will be able to produce enough shots to supply the world over the coming yearBy FRANK JORDANS Associated PressMay 10, 2021, 2:34 PM• 3 min readBERLIN — The head of German pharmaceutical company BioNTech said Monday that there is no need to waive patents on coronavirus vaccines because manufacturers will be able to produce enough shots to supply the world over the coming year.Ugur Sahin, the chief executive of BioNTech, rejected the U.S.-backed proposal to temporarily lift some intellectual property rights for vaccines in order to boost global supply during the ongoing pandemic.In a call with investors announcing the company’s first-quarter net profit of 1.13 billion euros ($1.37 billion), Sahin said BioNTech and its U.S. partner Pfizer had already delivered vaccines to more than 90 countries and more than doubled its forecast production capacity for the year.“We have now scaled the manufacturing capacity up to 3 billion doses in 2021, and more than 40% of these doses are expected to go to middle- and low-income countries,” Sahin said.Waiving patents would not ease supply shortages in the coming months,


Continue To Full Article